Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Qiagen (QGEN – Research Report) and Gain Therapeutics (GANX – Research Report).
Qiagen (QGEN)
Jefferies analyst Peter Welford maintained a Hold rating on Qiagen today and set a price target of EUR42.00. The company’s shares closed last Wednesday at $39.52.
According to TipRanks.com, Welford is a 4-star analyst with an average return of
Qiagen has an analyst consensus of Strong Buy, with a price target consensus of $50.07, a 26.5% upside from current levels. In a report issued on October 31, Kepler Capital also maintained a Hold rating on the stock with a EUR43.00 price target.
See the top stocks recommended by analysts >>
Gain Therapeutics (GANX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Wednesday at $2.82, close to its 52-week low of $2.56.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.00, implying a 228.7% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on QGEN:
- QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
- Qiagen, Element Biosciences partner to offer sequencing workflows
- Qiagen price target lowered to $46 from $50 at Baird
- Qiagen backs FY23 sales view of at least $1.97B, consensus $1.97B
- Qiagen reports Q3 EPS 50c, consensus 48c
